Pretreatment with Antiviral Preparation Kagocel Normalizes the Content of Bone Marrow Multipotent Stromal Cells and TNFα in Blood Serum of CBA Mice Disturbed by Administration of S. typhimurium Antigen Complex In Vivo and Maintains High Concentration of IL-10 and Th1 Cytokines


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Pretreatment with the active substance of antiviral preparation Kagocel, inductor of type I endogenous IFN, in a daily therapeutic dose (30 μg/mouse) 3 h prior to administration of S. typhimurium antigens to CBA mice reduced the number of bone marrow multipotent stromal cell (significantly increased by 3.2 times on the next day after antigen injection) to the initial level. Thus, activation of the stromal tissue induced by administration of the bacterial antigen was blocked. In addition, preliminary administration of Kagocel modulated the cytokine profile of the blood serum affected by S. typhimurium antigens: reduced 1.6-fold elevated concentration a proinflammatory cytokine TNFα to the control level (in 4 h after antigen injection) and maintained this level in 20 h after antigen administration. Kagocel also maintained the concentration of anti-inflammatory cytokine IL-10 at the level surpassing the normal by 1.6 times and high concentrations of Th1 cytokines (IL-2, IFNγ, and IL-12). These results suggest that Kagocel can reduce the immune response to bacterial antigens (similar to type I IFN [7]), which can contribute to its therapeutic and preventive effects in addition to its well documented antiviral activity and then this preparation can be used for the therapy of diseases accompanied by excessive or chronic inflammation.

Об авторах

Yu. Gorskaya

Laboratory for Regulation of Immunity and Immunological Tolerance

Автор, ответственный за переписку.
Email: uliya.gorskaya@nearmedic.ru
Россия, Moscow

A. Suslov

Laboratory of Mediators and Effectors of Immunity, N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of the Healthcare of the Russian Federation

Email: uliya.gorskaya@nearmedic.ru
Россия, Moscow

E. Semenova

Laboratory for Regulation of Immunity and Immunological Tolerance

Email: uliya.gorskaya@nearmedic.ru
Россия, Moscow

M. Konopleva

Laboratory of Mediators and Effectors of Immunity, N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of the Healthcare of the Russian Federation

Email: uliya.gorskaya@nearmedic.ru
Россия, Moscow

V. Nesternko

Laboratory for Regulation of Immunity and Immunological Tolerance

Email: uliya.gorskaya@nearmedic.ru
Россия, Moscow


© Springer Science+Business Media, LLC, 2017

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах